Gottlieb said he has heard Congress 'loud and clear' when it legalized hemp products, including CBD, in December and is putting together a working group of senior officials to work on the new rules.
The Food and Drug Administration will hold its first public hearings on CBD in April as the agency weighs rules allowing companies to add the popular cannabis-based compound to food, Commissioner Scott Gottlieb said Wednesday.
Gottlieb said he has heard Congress"loud and clear" when it legalized hemp products, including CBD, in December and is putting together a working group of senior officials to work on the new rules. The FDA will kick off its rulemaking process with a public hearing in April, he said. However, Gottlieb warned the committee that it will not be a"straightforward" process.
Gottlieb floated what a possible framework might look like. He suggested high concentrations might be regulated as a drug that has more stringent oversight while lower concentrations could be categorized as food products that come with an easier review process. "There is not a good proxy for us doing this through regulation, and if we get comments back and find this is sufficiently complicated for the agency, we will come back and have a conversation with Congress on with how we might be able to work together on this," Gottlieb said. He added that Congress may need to intervene with additional legislation if the FDA thinks it will take two or more years to implement the rules.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Wall Street thinks the $1 billion market CBD could explode to $16 billion by 2025In a new report, analysts at the investment bank Cowen highlight a marijuana and hemp compound called CBD as a massive opportunity for growth.
Consulte Mais informação »
'Wacky' drug price system keeps costs high for patients paying for prescriptions, FDA Chief saysRebates are a favorite target of pharmaceutical companies, who say pharmaceutical benefit managers extract huge discounts but keep them for themselves instead of sharing the savings with patients.
Consulte Mais informação »